Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differential expression of transcriptional genes in paclitaxel-resistant mouse gastric adenocarcinoma cell lines

ABSTRACT: Differential expression of transcriptional genes in paclitaxel-resistant mouse gastric adenocarcinoma cell lines

PROVIDER: PRJNA1243988 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR33380173_1.fastq.gz	Fastqsanger.gz
	SRR33380173_2.fastq.gz	Fastqsanger.gz
	SRR33380174_1.fastq.gz	Fastqsanger.gz
	SRR33380174_2.fastq.gz	Fastqsanger.gz
	SRR33380175_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 13

Similar Datasets

Differential expression of transcriptional genes in paclitaxel-resistant mouse gastric adenocarcinoma cell lines

Project description:Paclitaxel is commonly used as a second-line treatment for gastric cancer, but the mechanisms underlying paclitaxel resistance remain to be further investigated. To address this, we successfully established a mouse gastric adenocarcinoma cell line (MPC) from murine gastric adenocarcinoma organoids. Subsequently, a paclitaxel-resistant cell line (MPC-PTX) was generated through multi-cycle drug stimulation. This model provides a valuable tool for studying the mechanisms of paclitaxel resistance in gastric cancer.

2025-05-07 | GSE293310 | GEO

Expression profile of brazilian gastric adenocarcinoma cell lines

Project description:The ACP02 cell line was stablished from a primary diffuse adenocarcinoma (T3N2M0) and AGP01 cell was established from ascitic fluid cells from intestinal gastric adenocarcinoma (T3N2M1). mRNA samples from cell lines were amplified, labeled, and hybridized to the Affymetrix GeneChip Human Exon 1.0 ST array. The chip array data analysis was performed with Partek® software (http://www.partek.com).

2020-11-18 | GSE161689 | GEO

Expression profile of brazilian gastric adenocarcinoma cell lines

Project description:Expression profile of brazilian gastric adenocarcinoma cell lines

| PRJNA679084 | ENA

MicroRNA expression of primary gastric adenocarcinoma compared to non-cancer gastric tissue

Project description:Identification of the microRNA signature associated with human gastric adenocarcinoma.

2013-09-01 | GSE26595 | GEO

MicroRNA expression of primary gastric adenocarcinoma compared to non-cancer gastric tissue

Project description:Identification of the microRNA signature associated with human gastric adenocarcinoma. Total RNA obtained from 60 primary gastric cancer tissues and 8 surrounding non-cancer tissues was used for microarray analysis. For validation, real-time RT-PCR was performed.

2013-09-01 | E-GEOD-26595 | biostudies-arrayexpress

Intraperitoneal paclitaxel is a safe and effective therapeutic strategy for treating mucinous appendiceal adenocarcinoma

Project description:Appendiceal adenocarcinomas (AAs) are a rare and heterogeneous mix of tumors for which few preclinical models exist. The rarity of AA has made performing prospective clinical trials difficult, which has partly contributed to AA remaining an orphan disease with no chemotherapeutic agents approved by the FDA for its treatment. AA has a unique biology in which it frequently forms diffuse peritoneal metastases but almost never spreads via a hematogenous route and rarely spreads to lymphatics. Given the localization of AA to the peritoneal space, intraperitoneal (IP) delivery of chemotherapy could be an effective treatment strategy. Here, we tested the efficacy of paclitaxel given by IP administration using three orthotopic patient-derived xenograft (PDX) models of AA established in immunodeficient NSG mice. Weekly IP paclitaxel treatment dramatically reduced AA tumor growth in all three PDX models. Comparing the safety and efficacy of intravenous (IV) to IP administration, IP delivery of paclitaxel was more effective with reduced systemic side effects in mice. Given the established safety record of IP paclitaxel in gastric and ovarian cancers, and lack of effective chemotherapeutics for AA, these data showing the activity of IP paclitaxel in orthotopic PDX models of mucinous AA support the evaluation of IP paclitaxel in a prospective clinical trial.

2023-07-07 | GSE236502 | GEO

Spatial transcriptomic analysis of Gastric adenocarcinoma

Project description:Spatial transcriptomic analysis of Gastric adenocarcinoma

| PRJNA1029602 | ENA

Gene expression profiles in bone marrow of human gastric adenocarcinoma at stage III and stage IV

Project description:A secreted factor in bone marrow associated with metastatic gastric cancer was indentified through expression profiling in bone marrow of stage III and stage IV gastric adenocarcinoma. In the study presented here, bone marrow samples from patients with stage III or stage IV gastric adenocarcinoma were used to acquire expression profiles.

2013-10-22 | E-GEOD-41801 | biostudies-arrayexpress

Expression data of Human Gastric Adenocarcinoma

Project description:Anatomical staging is a critical, although imperfect, instrument to assess gastric cancer prognosis and define indication for surgery and adjuvant therapy. Despite recent advances, treatment results, as a whole, remain less than satisfactory. Thus, biomarkers are sorely needed to improve risk categorization and define new molecular targets for therapy. We used microarrays to identify genes differentially expressed according to prognosis of the patients. A cohort of 15 patients was prospectively identified with a histological diagnosis of gastric adenocarcinoma, submitted to surgery with curative intent. Two prognostic patient groups were defined, according to overall survival (short x long), with a 24 month cut-off. These groups were matched by known prognostic factors: TNM staging, histological subtype (intestinal/diffuse) and gender.

2012-09-01 | E-GEOD-38749 | biostudies-arrayexpress

Paclitaxel resistant MDA-MB-231 Cells and resensitization with bexarotene treatment

Project description:Acquired drug resistance represents a major challenge in chemo-therapy treatment for various types of cancers. We have found that the retinoid X receptorâselective agonist bexarotene (LGD1069, Targretin) was efficacious in treating chemo-resistant cancer cells. The goal of this microarray study was to understand the mechanism of bexaroteneâs role in overcoming acquired drug resistance using human breast cancer cells MDA-MB-231 as a model system and paclitaxel as model compound. After MDA-MB-231 cells were repeatedly treated with paclitaxel for 8 cycles with each cycle including a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium, MDA cells resistant to paclitaxel were developed and their growth was no longer inhibited by paclitaxel treatment. Those MDA cells with acquired drug resistance, when treated with paclitaxel and bexarotene in combination, could regain their sensitivity and their growth were again inhibited. Therefore, RNA samples from parental MDA-MB-231 cells, paclitaxel-resistant MDA cells treated with vehicle, paclitaxel alone or in combination with bexarotene, were used for perform global gene expression profiling with Affymetrix HG-U133A gene chips. Keywords: Drug Treatment MDA-MB-231 cells were exposed to regimens on a 10-day cycle: a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium. Paclitaxel resistant MDA-MB-231 cells (MDA-PR) were established within 8 cycles of such treatment (80 days). These MDA-PR cells were then treated with vehicle control, paclitaxel along, or the combination of 30 nM paclitaxel ( 3 days on and 7 days off) and 1 ÂµM Targretin (10 days on) in a new 10-day cycle for 3 months. Thus, there are four treatment groups, parent MDA cells, MDA-PR, MDA-PR treated with paclitaxel, MDA-PR treated with paclitaxel and bexarotene, and each group had four biological replicates.

2011-07-18 | E-GEOD-12791 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data